JPRN-UMIN000006823
Completed
Phase 2
Phase II study of S-1 plus irinotecan combined with biweekly cetuximab as 2nd-line chemotherapy in patients with wild type KRAS unresectable colorectal cancer, who had previously received oxaliplatin-based chemoterapy without CV port. (FUTURE 1103 STUDY) - Phase II study of S-1 plus irinotecan combined with biweekly cetuximab as 2nd-line chemotherapy in patients with wild type KRAS unresectable colorectal cancer, who had previously received oxaliplatin-based chemoterapy without CV port. (FUTURE 1103 STUDY)
Fukuoka Tumor Research(FUTURE)0 sites30 target enrollmentDecember 3, 2011
ConditionsColorectal Cancer
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Colorectal Cancer
- Sponsor
- Fukuoka Tumor Research(FUTURE)
- Enrollment
- 30
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) History of severe allergy 2\) Simultaneous or metachronous double cancers 3\) Symptomatic brain metastasis 4\) Severe infectious disease 5\) Severe complications (interstitial lung disease or pulmonary fibrosis, heart failure, kidney failure, hepatic failure, uncontrolable diabetes, Jaundice) 6\) Paralytic or mechanical bowel obstruction 7\) Massive pleural effusion or ascites 8\) Wattery diarrhea 9\) Patients who is receiving Atazanavir Sulfate or Flucytosine 10\) Pregnant or lactating women or women of childbearing potential 11\) Any other cases who are regarded as inadequate for study enrollment by the investigator.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Phase II study of S-1 plus irinotecan combined with bevacizumab as 2nd-line chemotherapy in patients with unresectable colorectal cancer, who had previously received oxaliplatin-based chemotherapy.Colorectal cancerJPRN-UMIN000006307Kyushu Study group of Clinical Cancer37
Completed
Not Applicable
Phase II study of S-1 combined with irinotecan in patients with advanced colorectal cancerJPRN-UMIN000001741Showa University School of Medicin40
Completed
Phase 2
Multicenter Phase II trial of Irinotecan plus S-1 with cetuximab (IRIS/Cet) in patients with EGFR positive and KRAS wild type of advanced/metastatic colorectal canceradvanced/metastatic colorectal cancerJPRN-UMIN000004882PO Hokkaido Gastrointestinal Cancer Study Group (HGCSG)80
Completed
Phase 2
A Phase II trial of irinotecan / S-1 (IRIS) + alfa (Panitumumab/Bevacizumab) as 2nd line chemotherapy for metastatic colorectal cancer (mCRC) A multicenter phase II trial of TS1 + Irinotecan (IRIS) + Panitumumab as second line treatment in patients with KRAS wild type unresectable advanced colorectal cancer (mCRC).metastatic colorectal cancerJPRN-UMIN000009317Yamaguchi University Department of Digestive Surgery and Surgical Oncology30
Completed
Phase 2
A Phase II trial of irinotecan / S-1 (IRIS) + alfa (Panitumumab/Bevacizumab) as 2nd line chemotherapy for metastatic colorectal cancer (mCRC) A multicenter phase II trial of TS1 + Irinotecan (IRIS) + Bevacizumab as second line treatment in patients with KRAS mutant type unresectable advanced colorectal cancer (mCRC).metastatic colorectal cancerJPRN-UMIN000009318Yamaguchi University Department of Digestive Surgery and Surgical Oncology30